Table 2.

Inhibition of proliferation by alisertib in tumor cell lines, as assessed by the BrdU cell proliferation assay

Cell lineAlisertib IC50 (nmol/L)
ColonHCT-11632 ± 10 (8)a
SW480431 ± 159 (8)
DLD-1469 (1)
LungH46016 (1)
BreastMDA-MB-231190 (1)
ProstatePC354 (1)
OvarianSKOV3111 (1)
PancreaticHPAC130 (1)
Lymphoma (DLBCLs)OCI-LY-343 (1)
OCI-LY-786 (1)
OCI-LY-1016 (1)
OCI-LY-1915 (1)
WSU50 (1)

Numbers in parentheses represent the number of experiments completed.

  • aNumbers represent average IC50 ± SD derived from the BrdU cell proliferation ELISA assay.